FOLD— AMICUS THERAPEUTICS, INC.

MaterialsBiotechnology$4.5B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Net product sales	$634.2M+20.0%	$528.3M+32.3%	$399.4M+21.3%	$329.2M
Cost of goods sold	$72.9M+37.8%	$52.9M+41.8%	$37.3M-3.3%	$38.6M
Gross profit	$561.3M+18.1%	$475.4M+31.3%	$362.0M+24.6%	$290.6M
Research and development	$135.8M+24.2%	$109.4M-28.2%	$152.4M-44.9%	$276.7M
Selling, general, and administrative	$383.5M+18.6%	$323.4M+17.5%	$275.3M+29.2%	$213.0M
Changes in fair value of contingent consideration payable	$0	$0-100.0%	$2.6M+139.6%	$1.1M
Loss on impairment of assets	$1.7M	$0-100.0%	$1.1M-82.9%	$6.6M
Restructuring charges	$0-100.0%	$9.2M	$0	$0
Depreciation and amortization	$7.5M-12.7%	$8.5M+8.6%	$7.9M+47.4%	$5.3M
Total operating expenses	$528.5M+17.3%	$450.5M+2.6%	$439.2M-12.6%	$502.8M
Income (loss) from operations	$32.8M+31.8%	$24.9M+132.2%	-$77.2M+63.6%	-$212.1M
Interest income	$3.3M-38.7%	$5.4M-23.6%	$7.1M+134.1%	$3.0M
Interest expense	-$46.2M+6.9%	-$49.6M+1.1%	-$50.1M-35.1%	-$37.1M
Loss on extinguishment of debt	$0	$0+100.0%	-$13.9M	$0
Other (expense) income	$10.2M+208.5%	-$9.4M+40.6%	-$15.9M-480.4%	$4.2M
Income (loss) before income tax	$191K+100.7%	-$28.8M+80.8%	-$150.1M+38.0%	-$242.0M
Income tax expense	-$27.3M+0.2%	-$27.4M-1744.2%	-$1.5M-127.1%	$5.5M
Net loss attributable to common stockholders	-$27.1M+51.7%	-$56.1M+63.0%	-$151.6M+35.9%	-$236.6M
Net loss attributable to common stockholders per common share - basic (in dollars per share)	-$0.09+50.0%	-$0.18+64.7%	-$0.51+37.8%	-$0.82
Net loss attributable to common stockholders per common share - diluted (in dollars per share)	-$0.09+50.0%	-$0.18+64.7%	-$0.51+37.8%	-$0.82
Weighted-average common shares outstanding - basic (in shares)	308.4M+1.3%	304.4M+3.1%	295.2M+2.1%	289.1M
Weighted-average common shares outstanding - diluted (in shares)	308.4M+1.3%	304.4M+3.1%	295.2M+2.1%	289.1M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.